Skip to content

Depression research published in 2024

Page 9 of 26: studies 161 to 180 of 512, newest first. Back to the depression overview

Studies

Target mechanisms of mindfulness-based programmes and practices: a scoping review.

BMJ mental health August 24, 2024 Shannon Maloney, Merle Kock, Yasmijn Slaghekke et al. 16 citations

Mindfulness-based programmes (MBPs) and practices have demonstrated effects in mental health and well-being, yet questions regarding the target mechanisms that drive change across the population remain unresolved. Five databases were searched for randomised controlled trials that evaluate the indirect effects (IEs) of an MBP or mindfulness practice in relation to mental health and well-being...

LSDDEP2: study protocol for a randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups trial of LSD microdosing in patients with major depressive disorder.

Trials August 24, 2024 Dimitri Daldegan-Bueno, Carina Joy Donegan, Anna Forsyth et al. 14 citations

Major depressive disorder (MDD) poses a significant global health burden with available treatments limited by inconsistent efficacy and notable side effects. Classic psychedelics, including lysergic acid diethylamide (LSD), have garnered attention for their potential in treating psychiatric disorders. Microdosing, the repeated consumption of sub-hallucinogenic doses of psychedelics, has emerged...

Prefrontal cortex molecular clock modulates development of depression-like phenotype and rapid antidepressant response in mice.

Nature Communications August 23, 2024 David H. Sarrazin, Wilf Gardner, Carole Marchese et al. 41 citations

Depression is associated with dysregulated circadian rhythms, but the role of intrinsic clocks in mood-controlling brain regions remains poorly understood. We found increased circadian negative loop and decreased positive clock regulators expression in the medial prefrontal cortex (mPFC) of a mouse model of depression, and a subsequent clock countermodulation by the rapid antidepressant...

DOI: 10.1038/s41467-024-51716-9 (opens in new tab) Full text (opens in new tab) Chronobiology Mental health Depression treatment Brain research

The role of psilocybin in depressive disorders

Current Medical Research and Opinion August 23, 2024 Jadwiga Najib 1 citation

Depression is a serious psychiatric disorder with a high incidence of morbidity and mortality and psilocybin with psychotherapy has emerged as a promising potential in the treatment of depressive disorders. A review of psilocybin use in patients with depressive disorders is presented.A search was conducted investigating the use of psilocybin in patients with depressive disorders and treatment...

Effect of esketamine on serum neurotransmitters in patients with postpartum depression: a randomized controlled trial.

BMC Anesthesiology August 19, 2024 Qinyu Jiang, Yu Qi, Meiyan Zhou et al. 11 citations

The development of postpartum depression has been linked to fluctuations in the levels of neurotransmitters in the human body, such as 5-hydroxytryptamine (5-HT), dopamine (DA), noradrenaline (Norepinephrine, NE), and brain derived neurotrophic factor (BDNF). Research has indicated that the antidepressant effect of esketamine are mediated by monoamine transmitters and neurotrophic factors....

DOI: 10.1186/s12871-024-02681-9 (opens in new tab) Full text (opens in new tab) Postpartum depression Serum neurotransmitters Mental health Esketamine ketamine/spravato +2

Comparison between Single-Dose and Two-Dose Psilocybin Administration in the Treatment of Major Depression: A Systematic Review and Meta-Analysis of Current Clinical Trials

Brain Sciences August 18, 2024 Gianmarco Salvetti, Daniele Saccenti, Andrea Stefano Moro et al. 16 citations

Current pharmacological treatments for major depressive disorder (MDD) are often only partially effective, with many patients experiencing no significant benefit, leading to treatment-resistant depression (TRD). Psilocybin, a classical serotonergic psychedelic, has emerged as a notable emerging treatment for such disorders. The aim of this systematic review and meta-analysis is to summarize and...

Nitrous Oxide Alters Functional Connectivity in Medial Limbic Structures in Treatment-Resistant Major Depression.

medRxiv August 17, 2024 Charles R Conway, Ben Julian A Palanca, Thomas Zeffiro et al. preprint

While nitrous oxide (N2O) has demonstrated antidepressant properties in treatment-resistant major depression (TRD), little is known about neural mechanisms mediating these effects. Employing serial resting-state functional magnetic resonance imaging (rs-fMRI), we compared spatiotemporal effects of inhaled N2O on brain functional connectivity in TRD patients (n=14) and non-depressed healthy...

Participation of Ca2+-Calmodulin-Dependent Protein Kinase II in the Antidepressant-Like Effects of Melatonin.

Molecular Pharmacology August 16, 2024 Armida Miranda-Riestra, Montserrat G Cercós, Citlali Trueta et al. 4 citations

Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine secreted by the pineal gland during the dark phase of the photoperiod. Its main function is the synchronization of different body rhythms with the dark-light cycle. Research on melatonin has significantly advanced since its discovery and we now know that it has considerable significance in various physiological processes, including...

Latina Mothers Recommendations on a Mindfulness-Based Cognitive Behavioral Therapy Group Intervention for Perinatal Depression.

Hispanic Health Care International August 14, 2024 Kritzia Merced, Uma D Parameswaran, Susan Dearden et al.

Introduction: Perinatal depression affects 5-15% of childbearing women. However, literature suggests that Latina women are twice as likely to experience depression during pregnancy. Group telehealth-based interventions are a promising approach to increasing access and reducing barriers to mental health. However, little is known about the experience that Latinas have with navigating this...

DOI: 10.1177/15404153241266585 (opens in new tab) Mindfulness Humans Depression, postpartum Focus groups +15

Heart Rate Variability as a Potential Predictor of Response to Intranasal Esketamine in Patients with Treatment-Resistant Depression: A Preliminary Report.

Journal of Clinical Medicine August 14, 2024 Lorenzo Moccia, Giovanni Bartolucci, Maria Pepe et al. 7 citations

Background: Esketamine has received approval as a nasal spray (ESK-NS) for treatment-resistant depression (TRD) and evidence from real-world investigations has confirmed the effectiveness of ESK-NS, albeit with interindividual differences in response. Heart rate variability (HRV), defined as the fluctuation in time interval between consecutive heartbeats, can be used to measure autonomic...

DOI: 10.3390/jcm13164767 (opens in new tab) Full text (opens in new tab) Esketamine Mood disorders Personalized medicine Mental-health +4

Study on the Effect of Self-Help Mindfulness Therapy on Rumination in Patients with Depression

Journal of Clinical and Nursing Research August 12, 2024 Ling Jiang, Sijia Mao, Minfang Qian et al.

Objective: To evaluate the nursing effect of self-help mindfulness therapy for patients with depression. Methods: 120 cases of depression patients admitted to the Department of Psychosomatic Disorders of our hospital between January 2020 and January 2023 were selected. After being grouped by the random draw method, 60 cases in the observation group adopted self-help mindfulness therapy and 60...

Psilocybin-assisted psychotherapy: Advancements, challenges, and future directions for treating resistant depression

Psychedelics August 12, 2024 Rodolfo Myronn de Melo Rodrigues

Depression is a global public health challenge that represents the world's largest cause of disability, especially in the context of traditional treatments. One potential solution being explored is psilocybin assisted psychotherapy (PAP) which shows promise for treating depression. A recent study by Rosenblat et al. explores the use of psilocybin in clinical mental care with promising results (1).

Psychometric properties of the Arabic version of the Nightmares Distress Questionnaire (NDQ-AV) in a community sample of adolescents.

BMC Psychiatry August 9, 2024 Roni Chaaya, Chen Jiang, Runtang Meng et al.

Background: The Nightmare Distress Questionnaire (NDQ), known and commonly used for its adequate psychometric properties, is the most widely used instrument for the measurement of nightmare distress. This study aimed to assess the psychometric properties of a newly translated Arabic version of the Nightmare Distress Questionnaire (NDQ-AV). Methods: A total of 546 Lebanese adolescents was...

Suicidal ideation following ketamine prescription in patients with recurrent major depressive disorder: a nation-wide cohort study.

Translational Psychiatry August 9, 2024 Yiheng Pan, Maria P Gorenflo, Pamela B. Davis et al. 14 citations

Ketamine has gained attention for its effective treatment for patients with major depressive disorder (MDD) and suicidal ideation; Despite numerous studies presenting the rapid efficacy, long-term benefit in real-world populations remains poorly characterized. This is a retrospective cohort study using TriNetX US Collaborative Network, a platform aggregating electronic health records (EHRs)...

DOI: 10.1038/s41398-024-03033-4 (opens in new tab) Full text (opens in new tab) Mental-health Ketamine-therapy Suicide-prevention Depression-treatment +1

REVOLUTIONIZING DEPRESSION TREATMENT: A PARADIGM SHIFT OF KETAMINE THERAPY – A SYSTEMATIC REVIEW

Asian Journal of Pharmaceutical and Clinical Research August 7, 2024 Yuvraj Kaushal, Pranav Goyal, Arshiya Sehgal

Objectives: Primary Objective: (1) The objectives of the study are as follows: assessment of the effectiveness of ketamine-based treatment in known patients of various subtypes of depression and (2) assessment of time of onset and duration along with routes of administration and safety of ketamine therapy. Secondary Objective: The objectives of the study are as follows: (1) evaluate changes in...

Comparative effect of different mindfulness-based intervention types and deliveries on depression in patients with breast cancer: a protocol for a systematic review and network meta-analysis.

BMJ Open August 7, 2024 Deqi Zhang, Wenxin Zhao, Lin Yuan et al. 1 citation

Breast cancer has become the most common cancer worldwide. Various types of mindfulness-based interventions (e.g., mindfulness-based cognitive therapy, mindfulness-based stress reduction) have been conducted in different delivery methods (including face to face and internet delivered) to help patients with breast cancer mitigate their depression. However, at present, there are no studies that...

DOI: 10.1136/bmjopen-2024-084564 (opens in new tab) Full text (opens in new tab) Breast tumours Mental health Meta-analysis Rehabilitation medicine +1

Non-improvement predicts subsequent non-response to repeated-dose intravenous ketamine for depression: a re-analysis of a 2-week open-label study in patients with unipolar and bipolar depression.

Translational Psychiatry August 6, 2024 Chengyu Wang, Xiaofeng Lan, Weijian Liu et al. 6 citations

There is insufficient evidence to guide dose and frequency optimization with repeated-dose ketamine for depression. This study assessed the value of symptomatic non-improvement after the first few ketamine infusions as a predictor of overall non-response in depression for early decision-making to discontinue treatment. A total of 135 individuals with major depressive disorder or bipolar...

DOI: 10.1038/s41398-024-03027-2 (opens in new tab) Full text (opens in new tab) Depression treatment Ketamine therapy Mental health research Treatment response prediction

Different hierarchical reconfigurations in the brain by psilocybin and escitalopram for depression

Nature Mental Health August 5, 2024 Gustavo Deco, Yonatan Sanz Perl, Samuel Johnson et al. 39 citations

Abstract Effective interventions for neuropsychiatric disorders may work by rebalancing the brain’s functional hierarchical organization. Here we directly investigated the effects of two different serotonergic pharmacological interventions on functional brain hierarchy in major depressive disorder in a two-arm double-blind phase II randomized controlled trial comparing psilocybin therapy (22...

Novel treatments of depression: bridging the gap in current therapeutic approaches

Exploration of Neuroscience August 5, 2024 Amit Jagtiani 6 citations

Depression poses a significant global health burden, yet current therapeutic approaches focusing on monoaminergic neurotransmission often fall short of achieving full remission and managing acute episodes effectively. This article explores novel treatment avenues beyond conventional monoaminergic approaches, focusing on emerging strategies targeting glutamatergic modulation,...

DOI: 10.37349/en.2024.00049 (opens in new tab) Full text (opens in new tab) Psychedelic-assisted psychotherapy Glutamatergic modulation Brain stimulation Anti-inflammatory agents +9